TP53 and triple-negative breast carcinoma: Furthermore, Yi et al. showed that a 4-h treatment with the boronic acid chalcone analog of combretastatin A-4, YK-3-237, caused deacetylation of the mutant M237I-p53 at lysine 382 (K382) by activating the expression of SIRT1 in a triple-negative breast cancer.